Browsing ICR Divisions by author "Cojocaru, Elena"
Now showing items 1-8 of 8
-
Adult soft tissue myoepithelial carcinoma: treatment outcomes and efficacy of chemotherapy.
Chamberlain, F; Cojocaru, E; Scaranti, M; Noujaim, J; Constantinou, A; et al. (OXFORD UNIV PRESS, 2019-12-27)Soft tissue myoepithelial carcinomas are a rare, malignant subgroup of myoepithelial tumours mostly arising in the extremities with equal predilection for women and men. The mainstay of management of localised disease is ... -
Clinical management and outcomes of primary ovarian leiomyosarcoma - Experience from a sarcoma specialist unit.
Cojocaru, E; Palahepitiva Gamage, G; Butler, J; Barton, DP; Thway, K; et al. (ELSEVIER SCIENCE INC, 2021-03-01)Ovarian sarcomas account for 1% of all ovarian malignancies and amongst these, primary ovarian leiomyosarcoma is the rarest subtype. Primary ovarian leiomyosarcoma has a very poor prognosis, with less than 20% of patients ... -
Efficacy of Gemcitabine-based Chemotherapy in Clear Cell Sarcoma of Soft Tissue.
Cojocaru, E; Thway, K; Fisher, C; Messiou, C; Zaidi, S; et al. (INT INST ANTICANCER RESEARCH, 2020-12-01)BACKGROUND/AIM: Clear cell sarcoma (CCS) is an aggressive sarcoma subtype, resistant to conventional anthracycline-based chemotherapy and radiation. The diagnosis is often challenging due to similarities with malignant ... -
Is the IDH Mutation a Good Target for Chondrosarcoma Treatment?
Cojocaru, E; Wilding, C; Engelman, B; Huang, P; Jones, RL (Springer Science and Business Media LLC, 2020-03-01)<jats:title>Abstract</jats:title><jats:p>Chondrosarcomas are rare cancers of bone that arise from the malignant transformation of cells of chondrocytic lineage. They are known to be resistant to systemic cytotoxic chemotherapy ... -
KIT-Associated Familial GIST Syndrome: Response to Tyrosine Kinase Inhibitors and Implications for Risk Management.
Brodey, A; Kounnis, V; Hawkes, L; Jones, RL; McVeigh, TP; et al. (OXFORD UNIV PRESS, 2022-08-05)Sporadic gastrointestinal stromal tumors (GIST) are rare tumors, with a median age at diagnosis of 60 years. Familial GISTs are very rare and typically associated with earlier onset, with an average age at diagnosis of 48 ... -
Multidisciplinary interventions in a specialist Drug Development Unit to improve family history documentation and onward referral of patients with advanced cancer to cancer genetics services.
Moss, CA; Cojocaru, E; Hanwell, J; Ward, S; Xu, W; et al. (ELSEVIER SCI LTD, 2019-06-01)BACKGROUND: Molecular aberrations in cancer may represent therapeutic targets, and, if arising from the germline, may impact further cancer risk management in patients and their blood relatives. Annually, 600-700 patients ... -
Real-world experience with doxorubicin and olaratumab in soft tissue sarcomas in England and Northern Ireland.
Gennatas, S; Chamberlain, F; Carter, T; Slater, S; Cojocaru, E; et al. (BMC, 2020-05-06)BACKGROUND: A randomised phase II trial demonstrated that the addition of olaratumab to doxorubicin significantly increased overall survival (OS) in patients with advanced soft tissue sarcomas (STS) compared to doxorubicin ... -
Telemedicine During the COVID-19 Pandemic: Impact on Care for Rare Cancers.
Smrke, A; Younger, E; Wilson, R; Husson, O; Farag, S; et al. (AMER SOC CLINICAL ONCOLOGY, 2020-06-01)PURPOSE: Many patients with cancer, often those with rare cancers such as sarcomas, travel long distances to access expert care. The COVID-19 pandemic necessitated widespread changes in delivery of cancer care, including ...